A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study door Spagnuolo V, Galli L, Poli A, Bigoloni A, Fumagalli L, Gianotti N, Nozza S, Ferrari D, Locatelli M, Lazzarin A, Castagna A

Volledige tekst